Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43

Benzinga · 3d ago
Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.